From Oncogene to Drug: Development of Small Molecule Tyrosine Kinase Inhibitors as Anti-Tumor and Anti-Angiogenic Agents

Oncogene - United Kingdom
doi 10.1038/sj.onc.1204102
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Small Molecule FLT3 Tyrosine Kinase Inhibitors

2012English

Recent Development of ATP-competitive Small Molecule Phosphatidylinostitol-3-Kinase Inhibitors as Anticancer Agents

Oncotarget
Oncology
2016English

Small Molecule Tyrosine Kinase Inhibitors in Pancreatic Cancer

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2008English

Neutralizing Antibody and Anti-Retroviral Drug Sensitivities of HIV-1 Isolates Resistant to Small Molecule CCR5 Inhibitors

Virology
Virology
2008English

Synthesis of Novel Sulfonamide-Based Calpain Inhibitors and Their Potential as Anti-Tumor Agents

English

ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: Thyroid Effects of Tyrosine Kinase Inhibitors

European Journal of Endocrinology
MedicineEndocrinologyMetabolismDiabetes
2014English

P1.13-24 EGFR-KDD Is Rare and Demonstrates Variable Anti-Tumor Response to Tyrosine Kinase Inhibitors in East Asian NSCLC Population

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Validation of a Cell-Based ELISA as a Screening Tool Identifying Anti-Alphavirus Small-Molecule Inhibitors

Journal of Virological Methods
Virology
2013English

Quality of Animal Experiments in Anti-Angiogenic Cancer Drug Development – A Systematic Review

PLoS ONE
Multidisciplinary
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy